Conference Coverage
Conference Coverage
U.S. study finds unexpectedly high prevalence of myasthenia gravis
A study of the NIH All of Us database shows a higher prevalence of myasthenia gravis than what has been reported in previous studies.
Conference Coverage
‘Hidden’ cognitive impairments in DMD may worsen outcomes
Long waits for neuropsychiatric evaluations make it difficult to get help, but an NIH tool may help.
Conference Coverage
First new treatment in 30 years for rare disease is effective, tolerable, convenient
A new subcutaneous injectable showed efficacy and tolerability in patients with chronic inflammatory demyelinating polyneuropathy.
Conference Coverage
Duchenne muscular dystrophy gene therapy safe, effective at 4 years
“What’s really striking, and in my mind the most impressive, is that when you follow these patients out 3 or 4 years ... you see there is this...
Conference Coverage
Enhanced natural killer cell therapy shows promise in Alzheimer’s
A phase 1 proof-of-concept trial showed that natural killer cell therapy reduced both amyloid and tau proteins and dramatically reduced the...
Conference Coverage
Genetic therapies bring change to neurology clinics
Advancements are set to alter the approach to some patients and inspire a demand for genetic counselors in neuromuscular clinics.
Conference Coverage
In myasthenia gravis, antibodies pass open-label tests
New class of therapies interfere with IgG recycling and have similar efficacy across multiple cycles of treatment.
Conference Coverage
No benefit of colchicine after stroke, TIA: CHANCE-3
“We require randomized trials with longer follow-up prior to abandoning this potential treatment.”
Latest News
Neurologic nuggets of wisdom for pediatric practice
Overall, actual seizures are less common than other neurologic events in children.
Conference Coverage
Promising new therapies for managing Tourette syndrome
One new device is “really exciting...It’s not invasive and is quite simple to use and could help a lot of people with Tourette syndrome.”
Conference Coverage
Subcutaneous ocrelizumab, ofatumumab ‘reassuring’ in MS
The study “makes me feel pretty comfortable that regardless of where you’re delivering the therapy, IV or subcutaneously, it’s getting in there...